help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on June 23, 2006, doi:10.1164/rccm.200602-160OC

Am. J. Respir. Crit. Care Med., Volume 174, Number 6, September 2006, 684-688

A more recent version of this article appeared on September 15, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200602-160OCv1
174/6/684    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wisnivesky, J. P
Right arrow Articles by Yankelevitz, D. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wisnivesky, J. P
Right arrow Articles by Yankelevitz, D. F

Submitted on February 3, 2006
Accepted on June 21, 2006

Diagnostic Percutaneous Transthoracic Needle Biopsy does not Affect Survival of Stage I Lung Cancer

Juan P Wisnivesky1*, Claudia I Henschke2, and David F Yankelevitz2

1 Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY, USA; Division of Pulmonary, Critical Care Medine, and Sleep Medicine, Mount Sinai School of Medicine, New York, NY, USA, 2 Department of Radiology, New York - Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, USA

* To whom correspondence should be addressed. E-mail: juan.wisnivesky{at}mssm.edu.

Rationale: Lung cancer dissemination has been cited as a potential adverse consequence of diagnostic percutaneous transthoracic needle biopsy (PTNB) of lung nodules. Despite multiple reports in the literature of malignant spread along the needle track, the potential effect of lung cancer dissemination following PTNB on survival is unknown. Objective: To evaluate whether diagnostic PTNB is associated with increased risk of lung cancer death. Methods: This study included 8,607 cases of surgically resected Stage I non-small-cell lung cancer diagnosed between 1991 and 1999 from the Surveillance, Epidemiology and End Results registry linked to Medicare records. Overall and lung cancer-specific survival of patients who had and did not have PTNB was compared using Kaplan-Meier curves. Stratified survival analyses and Cox regression were used to compare survival while adjusting for potential confounders. Results: Approximately 36% of patients underwent diagnostic PTNB. Overall and lung cancer-specific survival was not different for patients that underwent PTNB as part of their cancer diagnostic work-up and those who did not (p=0.57 and 0.46, respectively). In stratified and multivariate analysis, PTNB was not associated with an increased risk of death after controlling for age, race, income, access to care, comorbidities, tumor histology and size, and type of treatment received. Conclusions: In this large national sample, preoperative PTNB was not associated with increased risk of death. These data suggest that PTNB can be safely used for the work-up of pulmonary nodules when there is a suspicion of lung cancer.


Key words: lung cancer, diagnosis, needle biopsy, survival




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
D. Stav
Modalities for Diagnosis of Peripheral Lung Diseases
Am. J. Respir. Crit. Care Med., February 15, 2008; 177(4): 462 - 462.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Dubey and C. A. Powell
Update in Lung Cancer 2006
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 868 - 874.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society